GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (FRA:XE7C) » Definitions » Cyclically Adjusted Book per Share

Cardiff Oncology (FRA:XE7C) Cyclically Adjusted Book per Share : €21.93 (As of Mar. 2025)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cardiff Oncology's adjusted book value per share for the three months ended in Mar. 2025 was €0.985. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €21.93 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Cardiff Oncology's average Cyclically Adjusted Book Growth Rate was -21.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cardiff Oncology was -1.50% per year. The lowest was -9.10% per year. And the median was -5.30% per year.

As of today (2025-05-29), Cardiff Oncology's current stock price is €2.69. Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €21.93. Cardiff Oncology's Cyclically Adjusted PB Ratio of today is 0.12.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cardiff Oncology was 0.70. The lowest was 0.03. And the median was 0.09.


Cardiff Oncology Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cardiff Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Cyclically Adjusted Book per Share Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.38 28.92 31.27 26.96 23.65

Cardiff Oncology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.44 26.28 23.64 23.65 21.93

Competitive Comparison of Cardiff Oncology's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PB Ratio falls into.


;
;

Cardiff Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.985/134.9266*134.9266
=0.985

Current CPI (Mar. 2025) = 134.9266.

Cardiff Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201506 46.794 100.684 62.709
201509 118.349 100.392 159.062
201512 108.252 99.792 146.365
201603 89.278 100.470 119.896
201606 69.189 101.688 91.805
201609 56.132 101.861 74.353
201612 43.991 101.863 58.270
201703 23.223 102.862 30.462
201706 7.234 103.349 9.444
201709 6.257 104.136 8.107
201712 7.501 104.011 9.731
201803 4.645 105.290 5.952
201806 5.187 106.317 6.583
201809 3.131 106.507 3.966
201812 2.313 105.998 2.944
201903 1.894 107.251 2.383
201906 1.439 108.070 1.797
201909 0.939 108.329 1.170
201912 0.766 108.420 0.953
202003 0.505 108.902 0.626
202006 1.015 108.767 1.259
202009 1.083 109.815 1.331
202012 2.864 109.897 3.516
202103 2.792 111.754 3.371
202106 2.915 114.631 3.431
202109 2.870 115.734 3.346
202112 2.961 117.630 3.396
202203 2.728 121.301 3.034
202206 2.632 125.017 2.841
202209 2.639 125.227 2.843
202212 2.247 125.222 2.421
202303 2.017 127.348 2.137
202306 1.789 128.729 1.875
202309 1.632 129.860 1.696
202312 1.431 129.419 1.492
202403 1.253 131.776 1.283
202406 1.067 132.554 1.086
202409 0.913 133.029 0.926
202412 1.191 133.157 1.207
202503 0.985 134.927 0.985

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cardiff Oncology  (FRA:XE7C) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cardiff Oncology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.69/21.93
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cardiff Oncology was 0.70. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cardiff Oncology Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Industry
Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Cardiff Oncology Headlines

No Headlines